IP Library › Granted Patent US 9,630,924
Granted Patent B2
US 9,630,924 · App. 15/055,108 · Granted Apr 25, 2017

Heterocyclic compound

Inventors: Satoshi Yamamoto (Kanagawa, JP); Junya Shirai (Kanagawa, JP); Tsuneo Oda (Kanagawa, JP); Mitsunori Kono (Kanagawa, JP); Atsuko Ochida (Kanagawa, JP); Takashi Imada (Kanagawa, JP); Hidekazu Tokuhara (Kanagawa, JP); Yoshihide Tomata (Kanagawa, JP); Naoki Ishii (Kanagawa, JP); Michiko Tawada (Kanagawa, JP); Yoshiyuki Fukase (New York, NY); Tomoya Yukawa (Kanagawa, JP); Shoji Fukumoto (Hyogo, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D217/26A61K31/4375A61K31/472A61K31/4741C07D217/14C07D471/04C07D491/048C07D491/056C07D491/14C07F7/0812
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,630,924
App. No.
15/055,108
Granted
Apr 25, 2017
Kind
B2
Abstract

The present invention provides a heterocyclic compound having a RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.

Claims (2)

1. ((1R,2S)-2-(((5R)-5-((7-Fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)carbonyl)cyclopropyl)acetic acid or a salt thereof.

2. A method of inhibiting RORγt in a mammal, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

Priority Claims (2)
JP 2014-136359 · Jul 1, 2014 · national
JP 2014-262775 · Dec 25, 2014 · national
Continuity (2)
Continuation 14755439 · Jun 30, 2015
Related Publication 20160176872A1 · Jun 23, 2016